1. Indian Council of Medical Research. Evidence based advisory to address inappropriate use of convalescent plasma in covid-19 patients. 17 Nov 2020. https://www.icmr.gov.in/pdf/covid/techdoc/ICMR_ADVISORY_Convalescent_plasma_17112020_v1.pdf.
2. The REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with covid-19: preliminary report. MedRxiv 2021.01.07.21249390 [Preprint]. https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v2.
3. Pulla P. Is favipiravir good for covid-19? Clinical trial says no, press release says yes. The Wire 2020 Nov 25. https://science.thewire.in/the-sciences/favipiravir-glenmark-open-label-trial-primary-endpoints-efficacy-cure-times-misleading-press-release.
4. Kumar S de Souza R Nadkar M . A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of itolizumab in moderate to severe ARDS patients due to covid-19. medRxiv 2020.12.01.20239574 [Preprint]. https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.
5. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia